Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620567
Title:
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Authors:
Califano, Raffaele; Greystoke, A; Lal, R; Thompson, J; Popat, S
Abstract:
Anaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2-7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a next generation ALK inhibitor (ALKi), approved by the European Medicines Agency in 2015. In the first-in-human, phase I study, ceritinib demonstrated rapid and durable responses in ALK patients previously treated with a different ALKi and in those who were ALKi-naive. As ceritinib is starting to be used routinely for the treatment of patients with ALK+ NSCLC, experience is growing with regard to ideal therapy management. In this review we provide a brief background to the development of ceritinib. The optimal treatment management and adverse events associated with ceritinib in clinical trials and in clinical practice are then discussed in detail, and where applicable, an expert consensus on specific recommendations are made. In clinical trials, the most common adverse events related to ceritinib are nausea, vomiting, and diarrhea. However, the majority of these are mild and, in the opinion of the authors, can be effectively managed with dose modifications. Based on clinical data, ceritinib has demonstrated efficacy as a first-line therapy and in patients who have relapsed on crizotinib, including those with brain metastases at baseline. Unfortunately, at some point, all patients experience progressive disease, with the central nervous system being a common site of metastases. Recommendations are made for continuing treatment beyond disease progression as long as a clinical benefit to patients is observed. Here, we review management of ceritinib treatment and adverse events and make recommendations on optimal management of patients.
Affiliation:
The Christie Hospital NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester
Citation:
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. 2017, 111:51-58 Lung Cancer
Journal:
Lung Cancer
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620567
DOI:
10.1016/j.lungcan.2017.06.004
PubMed ID:
28838397
Type:
Article
Language:
en
ISSN:
1872-8332
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCalifano, Raffaeleen
dc.contributor.authorGreystoke, Aen
dc.contributor.authorLal, Ren
dc.contributor.authorThompson, Jen
dc.contributor.authorPopat, Sen
dc.date.accessioned2017-09-22T15:37:33Z-
dc.date.available2017-09-22T15:37:33Z-
dc.date.issued2017-09-
dc.identifier.citationManagement of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. 2017, 111:51-58 Lung Canceren
dc.identifier.issn1872-8332-
dc.identifier.pmid28838397-
dc.identifier.doi10.1016/j.lungcan.2017.06.004-
dc.identifier.urihttp://hdl.handle.net/10541/620567-
dc.description.abstractAnaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2-7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a next generation ALK inhibitor (ALKi), approved by the European Medicines Agency in 2015. In the first-in-human, phase I study, ceritinib demonstrated rapid and durable responses in ALK patients previously treated with a different ALKi and in those who were ALKi-naive. As ceritinib is starting to be used routinely for the treatment of patients with ALK+ NSCLC, experience is growing with regard to ideal therapy management. In this review we provide a brief background to the development of ceritinib. The optimal treatment management and adverse events associated with ceritinib in clinical trials and in clinical practice are then discussed in detail, and where applicable, an expert consensus on specific recommendations are made. In clinical trials, the most common adverse events related to ceritinib are nausea, vomiting, and diarrhea. However, the majority of these are mild and, in the opinion of the authors, can be effectively managed with dose modifications. Based on clinical data, ceritinib has demonstrated efficacy as a first-line therapy and in patients who have relapsed on crizotinib, including those with brain metastases at baseline. Unfortunately, at some point, all patients experience progressive disease, with the central nervous system being a common site of metastases. Recommendations are made for continuing treatment beyond disease progression as long as a clinical benefit to patients is observed. Here, we review management of ceritinib treatment and adverse events and make recommendations on optimal management of patients.en
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en
dc.titleManagement of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchesteren
dc.identifier.journalLung Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.